Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Sep 16;31(30):3782–3790. doi: 10.1200/JCO.2012.47.4007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by American Society of Clinical Oncology

PMC Copyright notice

Fig 1. — Survival of patients stratified by donor KIR2DL1 functional allelic groups. Shown are the overall survival of (A) the entire cohort of 313 transplantation recipients, (B) the 256 patients with malignant disease, (C) the 231 patients with a hematologic malignancy, and (D) the patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) displayed separately after receiving a KIR2DL1-R²⁴⁵ homozygous (RR), KIR2DL1-R²⁴⁵/C²⁴⁵ heterozygous (RC), or KIR2DL1-C²⁴⁵ homozygous (CC) graft. P_RR/RC, P value between RR and RC group; P_RR,RC/CC, P value comparing RR and RC groups with CC group; ALL:RR, patients with ALL who received an RR donor graft; ALL:RC, patients with ALL who received an RC donor graft; ALL:CC, patients with ALL who received a CC donor graft; AML:RR, patients with AML who received an RR donor graft; AML:RC, patients with AML who received an RC donor graft; AML:CC, patients with AML who received a CC donor graft; P×RR,RC/CC, P value when comparing RR and RC groups with CC group for patients with the diagnosis of AML or ALL as indicated; P_RR, P_RC, and P_CC, P values when comparing ALL and AML patients who received a similar RR, RC, or CC donor graft.